Gradalis is a biotechnology company based in Carrollton, TX, specializing in the development and commercialization of personalized therapeutics for cancer treatment. Their flagship product, Vigil, is an immunotherapy platform being developed for multiple advanced cancer indications.
Under the leadership of CEO Steven Engle, who brings extensive experience from his previous roles at CohBar and XOMA, Gradalis is dedicated to advancing innovative cancer therapies. The company's Chief Scientific Officer, Dr. John Nemunaitis, is a renowned oncologist with over 30 years of experience in cancer research and treatment. With a team of experienced professionals, Gradalis is committed to making a significant impact in the field of personalized cancer therapeutics.
Generated from the website